MAOB and Parkinson disease: L-dopa, selegiline (MAO-B inhibitor), and Amantadine are given with L-dopa alone or in combination, especially during the late stage of PD, are promising innovative agents to have the potential to slow or reduce the PD progression (DeMaagd and Philip, 2015).